1265789-88-5 Usage
Uses
Used in Pharmaceutical Industry:
S6K-18 is used as a potent and selective inhibitor for the S6K enzyme, which is involved in cellular growth and proliferation. By inhibiting the S6K enzyme, S6K-18 has the potential to be used in the development of therapeutics for various diseases, particularly those characterized by uncontrolled cell growth, such as cancer.
Used in Cancer Research:
S6K-18 is used as a research tool to study the role of the S6K enzyme in cancer cell growth and proliferation. By understanding the effects of S6K-18 on the S6K enzyme, researchers can gain insights into the molecular mechanisms underlying cancer development and progression, which may lead to the discovery of novel therapeutic strategies for cancer treatment.
Used in Drug Development:
S6K-18 is used as a lead compound in the development of new drugs targeting the S6K enzyme. Its potent and selective inhibition of S6K makes it a valuable starting point for the design and synthesis of more effective and specific inhibitors, which could be used in the treatment of diseases associated with the dysregulation of the S6K pathway.
Check Digit Verification of cas no
The CAS Registry Mumber 1265789-88-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,6,5,7,8 and 9 respectively; the second part has 2 digits, 8 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1265789-88:
(9*1)+(8*2)+(7*6)+(6*5)+(5*7)+(4*8)+(3*9)+(2*8)+(1*8)=215
215 % 10 = 5
So 1265789-88-5 is a valid CAS Registry Number.
1265789-88-5Relevant articles and documents
Potent and selective thiophene urea-templated inhibitors of S6K
Ye, Ping,Kuhn, Cyrille,Juan, Miret,Sharma, Rahul,Connolly, Brendan,Alton, Gordon,Liu, Hu,Stanton, Robert,Kablaoui, Natasha M.
, p. 849 - 852 (2011)
S6K1 (p70 S6 kinase-1) is thought to play a critical role in the development of obesity and insulin resistance, thus making it an attractive target in developing medicines for the treatment of these disorders. We describe a novel thiophene urea class of S6K inhibitors. The lead matter for the development of these inhibitors came from mining the literature for reports of weak off-target S6K activity. These optimized inhibitors exhibit good potency and excellent selectivity for S6K over a panel of 43 kinases.
